VEEA doubles again with no stated reason
VEEA is the biggest move on the list by a wide margin, up 59.9% to close at $3.47 from a $2.17 previous close, on volume of 79.9 million shares against a 20-day average of about 5.6 million, roughly 2.5 times normal, and a range of $2.92 to $4.08 on the day. The only item behind it is a Yahoo Finance quote page, which carries no news or filing explaining the move. For context from that page: market cap about $216 million, trailing revenue $491k, net loss to common of $12.25 million, total cash $887k, debt-to-equity 167%, and 45 employees. The stock is up 102.9% over one month but still down 72.8% year to date and down 75.1% over a year, with a 52-week range of $1.34 to $18.68. If you want a reason for today, it isn't in the material.
VerifyMe becomes OpenWorld
VerifyMe's merger closed and the combined company began trading on Nasdaq as OPNW, renamed OpenWorld, Inc. The VRME line shows up 10.3%, though the article's own ticker box for OPNW reads -38.31%, so the quote you're looking at and the post-conversion ticker are not telling the same story. OpenWorld works in real-world asset tokenization, turning cash flows from operating businesses and physical assets into tokenized products, and says it has advised on projects representing over $66 billion in aggregate network value and supported more than 20 venture-backed companies, with backers named including a16z, Multicoin, Dragonfly and Founders Fund. Matthew Shaw is Chairman and CEO, Russ McMeekin is Group President, formerly a Honeywell senior executive. The company plans a dual listing on Figure OPEN, a blockchain trading platform, expected operational by November 2026. Maxim Group was OpenWorld's exclusive financial advisor. There is also a headline-only VerifyMe 8-K covering a Regulation FD disclosure and exhibits.
AMC down 8% with nothing in the news to match
AMC fell 8.0%, and neither item on it explains that. The full-text piece is a product announcement: a birthday party booking platform offering up to 25% off private theatre rentals at roughly 300 US locations, bookable one to six weeks ahead, with new food and beverage party packs and digital invitations through an Evite partnership. Evite data cited in the release says AMC-hosted party attendance rose nearly 25% year over year and that about 70% of theatre events on the platform are kid and teen birthdays, typically booked 25 days ahead for weekends. AMC runs about 850 theatres and 9,600 screens globally. Separately, a headline-only 8-K covers a departure or election of directors and officers with compensatory arrangements. That filing is the one worth opening if you want to know what moved it.
Credo up 7.9% on a valuation note
Credo rose 7.9% to $210.17, and the item covering it is a GuruFocus automated valuation piece rather than company news, so no operating cause is given. Their GF Value is $268.33, making the stock 21.7% below that estimate, with a GF Score of 85 out of 100, momentum ranked 10 of 10, growth 9, valuation 8, but profitability only 4. Trailing P/E is 75.0x against a five-year median of 131.5x, forward P/E 33.3x. The same note flags $462.3 million of insider selling over the past twelve months with no insider buying, and 12 gurus holding, 6 adding, 8 trimming. Year to date the stock is up 46.1%, inside a 52-week range of $86.49 to $308.67.
Vicor up 6.8% on a second guidance raise
Four items cover Vicor from two angles and they agree on the facts. Vicor raised its third-quarter 2026 revenue outlook for the second time in the quarter, now expecting growth of more than 30% quarter over quarter, up from more than 20% and an original forecast of roughly 10%. The increase comes from a recently announced non-exclusive Vertical Power Delivery royalty agreement with an AI original equipment manufacturer, and Needham expects this to be Vicor's largest revenue quarter from a single licensee to date, with some of the upside likely catch-up payments from prior quarters, as in past licensing deals. Needham's N. Quinn Bolton kept a Buy and raised the target to $350 from $320, based on 42 times his 2028 next-generation EPS estimate of $8.37, and lifted FY26, FY27 and FY28 estimates. Earlier context in the same piece: FY26 revenue guidance went to over $600 million from $570 million, and the company is building two new fabs in New Hampshire, ChiP Fab-2 and Fab-3. The GuruFocus items push the other way on price, putting GF Value at $69.99 against prices quoted between $288.94 and $308.59, calling it 313% to 341% overvalued, with trailing P/E of 92.8x to 99.1x versus a 74.2x five-year median, a GF Score of 80 with valuation ranked 1 of 10, and $410.6 million of insider selling over twelve months, $24.5 million of it in the last three, with no buying.
Marathon Petroleum up 6.3% on refining tightness
Marathon rose 6.3% to $420.15, now up about 146% year to date and near its 52-week high of $431.08. UBS reiterated Buy with a $450 target after hosting MPC and MPLX management for investor meetings in Boston. Management was constructive on refining into 2026: the Middle East conflict has depleted global product inventories, Russian refinery outages have tightened product markets further, and Venezuelan barrels reaching the US Gulf Coast is another positive. Management's view is that even if both conflicts end, margins could take more than six months to normalize, and that the new normal settles above the prior cycle average. The piece notes 11 analysts recently revised earnings higher, a target range of $236 to $472, and earlier moves: UBS up to $450 from $321, Jefferies down to Hold at $413 on balanced risk-reward, Freedom Broker up to Hold at $297. It also cites US diesel at a record $6.06 a gallon. Three GuruFocus pieces cut against that: GF Value $229.59 versus the current price, calling it 83% overvalued, GF Score 60 with profitability 8 of 10 but growth 2, valuation 1 and momentum 3, a one-star predictability rating, P/E of 14.5x against a 12.2x median, and $13.9 million of insider sales with no buying. On flows, ETFs were net sellers of $16.6 million of MPC on Sept 29, with XLE trimming $13.3 million and XOP $3.5 million, and XLE sold a further $7.5 million on Sept 30. Both XLE and XOP cut every single position in those sessions with no buys at all, so the MPC selling is part of a blanket energy trim, not a name-specific call.
Xenon rallies on CEO and CFO buying
Xenon was up 4.7%, and the cause is clear across four items. Form 4 filings covering trades on Sept 30 show CEO Ian Mortimer bought 30,000 shares at about $37.38 and CFO Thomas Patrick Kelly bought 15,000 at about $37.32, roughly $1.68 million combined. Mortimer's direct holding rose sharply, reported as up 88% to about 49,900 shares in one account and more than 150% in the other, and it was Kelly's first disclosed open-market purchase. The buying follows a roughly 35% drop during September tied to an enrollment pause in Xenon's depression trial on safety concerns, leaving the stock just above its 52-week low of $36.07. Lead candidate azetukalner has been submitted to the FDA for focal onset seizures. Consensus is Moderate Buy with an average target of $70.27. Note the tension: the same twelve-month window shows $23.0 million of insider selling and no buying before these two trades, and GuruFocus puts the GF Score at 31 out of 100, with financial strength 7 of 10 on a 21.0 current ratio and 0.01 debt-to-equity, but zeros for profitability and growth, and a price-to-sales ratio of 414x.
Analyst actions and headline-only movers
These are headline-only, so what follows is what the headlines state. Navitas was up 4.4%, flagged in a GuruFocus valuation note citing GF Value of $2.98 against a $12.12 price. Iovance fell 4.0% on a day with two items: its consensus price target was raised 34.74% to $13.06, and it appointed Noah Berkowitz as chief medical officer. Incyte was down 3.5% with Wells Fargo maintaining and raising its target to $128. BigBear.ai was up 3.4%, with a headline noting a 46.73% increase in the price target on its equity warrant to $0.14, and a separate chart note reading BBAI +7.4% on 1.6 times its own ATR20 at 0.9 times average volume, which does not match the 3.4% on your line. AST SpaceMobile fell 3.1% on a B. Riley downgrade with the target cut to $65, attributed in the headline to pricing concerns, alongside a Form 4 and unusual options activity in ASTS. Sandisk rose 2.7%, with one headline citing a new $2,100 price target as AI keeps NAND supply tight.
Netflix, Broadcom and the AI financing story
Netflix fell 2.5%, and the headline cluster points one way: the co-CEO publicly said the business is not growing as fast as he wants, with several outlets framing the 2% decline as the market's reaction to that. Separately Guggenheim maintained Buy and raised its target to $80, and Netflix announced a content partnership with Filmin in Spain. Broadcom was down 2.1% on a dense set of headlines about the same thing: it is assembling financing, variously described as $60 billion in total and $42 billion to lend to Anthropic, to fund AI chips, with one headline saying the stock fell as the $42 billion financing tied it to Anthropic and another framing it as a new layer of AI risk. UBS reiterated Buy on the AI revenue outlook. ETF flows on Broadcom were positive in both sessions covered, 51 funds adding on Wednesday and $143.0 million of net ETF buying on Tuesday.
Rocket Lab, SpaceX, Apple and the rest
Rocket Lab was up only 1.1% but has the most items: Citi initiated coverage at Buy citing launch backlog and commercial space growth, the company landed what headlines call its biggest-ever Electron deal, a 20-mission agreement with Synspective, and Cathie Wood's ARK bought roughly $16 million of the stock while selling Palantir. One headline also refers to a prior 43% plunge. SpaceX was down 1.8% across a long headline list with no single driver: Crew-13 launched to the ISS, Alphabet's Project Suncatcher AI chip prototype flew on a SpaceX rocket, the Pentagon tapped Musk on future warfare technology, and Musk cut the 2027 Starship launch cadence. Apple slipped 0.8%; Morgan Stanley lowered its target to $355 from $360 while keeping Overweight and describing a major product cycle under new CEO John Ternus, Needham reiterated Hold citing Meta competition risk, and SVP Jennifer Newstead sold $806,495 of stock. Oracle was up 0.6% on a Tencent cloud deal, confirmation that flooding reached but spared its $18 billion Project Jupiter data center, a Citizens reiteration at Outperform with a $285 target, and a $3.48 million open-market purchase by director Stephen Rusckowski. Worth a glance even with no move: a quoted Vertiv item has the CEO raising the organic revenue CAGR target through 2030 to 20–22% from a prior 12–14%, saying pipelines are strengthening and sales cycles accelerating. Everything else on the list, including Teva, TSM, Costco, Nebius, Joby, Canaan, Amphenol, Revolution Medicines and the ETF flow notes, is sub-1.5% moves with routine filings, fund-flow summaries or single analyst lines behind them.
VEEA up 59.9% with no news behind it
Veea closed up 59.9% at $3.47, a move of 1.2 times its own ATR20 on volume of roughly 79 million shares against a 4.3 million 20-day average. The only item behind it is the Yahoo Finance quote page, which carries no news story, so there is no stated reason for the move in the material. What the page does show: a day range of $2.92 to $4.08, a 52-week range of $1.34 to $18.68, and a one-month gain of 103% sitting against a 72.8% decline year to date and a 75.1% drop over a year. The company is an edge-computing hardware and software business in New York with 45 employees, trailing twelve-month revenue of $491,000, a net loss of $12.25 million, total cash of $887,000, debt-to-equity of 167%, and a market cap of about $216 million. Shares gave back 1.15% after hours.
VerifyMe becomes OpenWorld
VRME is up 10.3%. VerifyMe's business combination with OpenWorld closed and the combined company began trading on Nasdaq as OPNW, with the name change effective the same day. OpenWorld works in real-world asset tokenization, turning cash flows from operating businesses and physical assets into tokenized financial products for institutional investors; founded in 2023, it says it has advised on projects representing over $66 billion in aggregate network value and supported more than 20 venture-backed companies including names funded by a16z, Multicoin, Dragonfly and Founders Fund. Matthew Shaw becomes Chairman and CEO, with former Honeywell executive Russ McMeekin as Group President. Outgoing VerifyMe CEO Adam Stedham framed the merger as the clearest path to shareholder value. The company also plans a dual listing on the blockchain platform Figure OPEN, which it expects operational by November 2026. Maxim Group advised OpenWorld. Note that the in-article quote block shows OPNW down 25.94%, against the +10.3% on the VRME line. Two 8-K filings accompany this, one covering the completion of the acquisition, change in control, unregistered equity sales and director and officer changes, the other a Regulation FD disclosure.
AMC down 8% on a day it announced a party program
AMC fell 8.0%. The only full article on it is a product announcement, not a reason for the decline: AMC launched a birthday party booking platform offering up to 25% off private theatre rentals at roughly 300 US locations, bookable one to six weeks ahead, with new food and beverage packs and an Evite partnership for branded digital invitations. Evite data cited in the release says AMC-hosted party attendance rose nearly 25% year over year and that almost 70% of theatre events on the platform are kid and teen birthdays. AMC runs about 850 theatres and 9,600 screens. Separately, an 8-K filed today covers departure or appointment of directors and officers and compensatory arrangements, headline only, so there's no detail on who.
Vicor guidance raised twice, Needham to $350
Vicor is up 6.8%, and this is the most substantive story in the list. On September 30 the company lifted third-quarter 2026 sequential revenue growth guidance from more than 20% to more than 30%, citing higher-than-expected royalties from its first non-exclusive licence for Vertical Power Delivery technology. That was the second raise in roughly ten days; the original guide was about 10%, raised to over 20% after a September 17 licence to a new AI OEM. VPD mounts current multipliers directly beneath high-performance processors to cut power loss in AI data centres, and licensees can buy modules from Vicor or from unlicensed suppliers, with discounts on royalties if they buy from Vicor. CEO Patrizio Vinciarelli has said four OEMs and hyperscalers now hold licences and that the first VPD patent was only recently asserted. Needham's N. Quinn Bolton kept a Buy and raised the target to $350 from $320, based on 42 times his 2028 next-generation EPS estimate of $8.37, and thinks the upside partly reflects catch-up payments from prior quarters, consistent with past licensing deals; he expects this to be Vicor's largest revenue quarter from a single licensee. The same note mentions full-year 2026 revenue guidance above $600 million, up from $570 million, and plans for two new New Hampshire fabs, ChiP Fab-2 and Fab-3. The counterweight comes from GuruFocus, which puts the stock at $288.94 against a GF Value of $69.99, a trailing P/E of 92.76 versus a five-year median of 74.21, a GF Score of 80 with valuation ranked 1 out of 10, and insider selling of $410.6 million over twelve months with no insider buying, plus six of seven tracked gurus trimming.
Marathon Petroleum on tight product markets
MPC is up 6.3%. UBS reiterated Buy with a $450 target after hosting Marathon and MPLX management in Boston. Management was constructive on refining into 2026: the Middle East conflict has drawn down global product inventories, Russian refinery outages have tightened markets further, and Venezuelan barrels reaching the US Gulf Coast are a further positive. They argued that even if both conflicts ended, normalising margins could take more than six months, and that the new normal settles above the prior cycle average. The note says the stock is up 146% year to date to $404.50, near its 52-week high, with sell-side targets spanning $236 to $472, and references earlier moves: UBS had already raised its target from $321, Jefferies downgraded to Hold at $413 on balanced risk-reward, and Freedom Broker moved to Hold at $297. US diesel hit $6.06 a gallon. GuruFocus takes the other side, scoring MPC 60 out of 100 with profitability 8/10 but growth 2/10, GF Value 1/10, momentum 3/10 and one-star predictability, noting the 55% three-month rally. Three other MPC items are headline-only ETF flow notes, including one saying ETFs were net sellers of the stock on September 29.
Xenon on insider buying
XENE is up 4.7%, with four headline-only items all pointing the same way: the CEO and CFO bought about $1.7 million of stock, with CFO Thomas Kelly purchasing 15,000 shares in the open market.
Smaller movers on single headlines
Navitas is up 4.4% on a headline saying it got early FTC clearance for the Claros acquisition. Iovance is down 4.0%; headlines note it appointed Noah Berkowitz as chief medical officer and that Wells Fargo raised its target to $18 while keeping its rating. Incyte is off 3.5%, with Wells Fargo raising its target to $128. BigBear.ai is up 3.4%, flagged only as a 1.6x ATR move on below-average volume. AST SpaceMobile is down 3.1% against headlines about shipping three more BlueBird satellites and unusual option activity.
SanDisk, Netflix, NetApp
SanDisk is up 2.7%, with headlines citing a $2,100 price target tied to tight NAND supply, a Citi reiteration after Micron's results, and its inclusion in a large-cap momentum list. Netflix is down 2.5%, and the cluster of headlines all trace to the same thing: the co-CEO publicly saying the company is not growing as fast as he wants, with live content cited in one of them. Guggenheim kept a Buy and raised its target to $80. NetApp is up 2.4% on the launch of its Novus storage architecture.
Broadcom and the Anthropic loan
AVGO is down 2.1%. The driver across roughly eight headlines is one disclosure, from an IPO prospectus: Broadcom will lend Anthropic up to $42 billion for infrastructure lease agreements, letting Anthropic lease its chips. Coverage splits between framing it as strengthening Broadcom's position in AI chip design and framing it as added AI credit risk. A separate headline notes Netlist seeking an AI-memory import ban.
SpaceX, Rocket Lab and the rest of the space names
SPCX is down 1.8% on a heavy but low-signal headline flow: Crew-13 launch coverage, Alphabet launching AI chips into orbit on a SpaceX rocket, Musk cutting the Starship launch schedule for next year, Pentagon work, Starlink on United and American, and $110.1 million of ETF buying on Tuesday. Rocket Lab is up only 1.1% despite the most concrete news in the group, a 20-mission Electron contract with Synspective described as its largest ever, plus a Citi initiation at Buy. Red Cat is down 2.0% on a Blue Ops partnership with Florida Atlantic University, and Joby is down 1.6% with a headline noting a 52-week low at $5.93.
Quieter names
Take-Two is down 1.9% after signing a new long-term Xbox publisher licence with Microsoft, with a matching 8-K. Nebius is down 1.5% on a busy but mixed flow: it acquired Israeli AI startup Inferize to improve GPU efficiency, signed a 12-year, 50 MW data centre deal with AIB, and was initiated at Outperform by William Blair. Apple is down 0.8% with a large pile of headlines that mostly repeat two notes, Morgan Stanley cutting its target to $355 from $360 while keeping Overweight and pointing to a major product cycle under new CEO John Ternus, and Needham reiterating Hold on Meta competition risk. Oracle is up 0.6%, with headlines saying Project Jupiter escaped major flood damage and that Tencent is leasing 100,000 chips from Oracle for about $7 billion. Costco, Generac, Teva, TSMC, TeraWulf, Exelixis, Aflac and Bank Bradesco all moved less than 1% and carry only routine headlines.
VerifyMe becomes OpenWorld on Nasdaq
The largest move on the list is VRME, up 10.3%, and the reason is structural rather than operational. VerifyMe's business combination closed and the company began trading on Nasdaq as OpenWorld, Inc. under the ticker OPNW, having changed its name effective the same day. OpenWorld works in real-world asset tokenization, building infrastructure to turn cash flows from operating businesses and physical assets into tokenized financial products for institutional investors. Founded in 2023, it says it has advised on projects representing over $66 billion in aggregate network value and supported more than 20 venture-backed companies, with backers including a16z, Multicoin, Dragonfly and Founders Fund. Matthew Shaw becomes Chairman and CEO; Russ McMeekin, previously a senior Honeywell executive, becomes Group President. Former VerifyMe CEO Adam Stedham framed the merger as the clearest path to shareholder value. The company also plans a dual listing on Figure OPEN, a blockchain trading platform, which it expects operational by November 2026. Maxim Group advised OpenWorld. Two 8-K filings accompany this, headline-only here, covering completion of the acquisition, change in control, unregistered equity sales, officer changes and a Reg FD disclosure.
Brazilian banks move together
Itaú and Bradesco both jumped, ITUB up 5.4% and BBD up 4.8%, and the only substantive item behind either is a Bradesco insider filing. The two chart items flag the size of the moves relative to their own volatility, ITUB roughly 1.5 times its 20-day ATR and BBD about 1.6 times, both on below-average volume, 0.7 and 0.6 times the 20-day average respectively. Neither chart page carried any explanation, and the ITUB link resolved to a consent screen with no article at all. The Bradesco item is a GuruFocus report that executive officer Marcello Di bought 57,160 shares on September 29, doubling his direct holding to 113,004 shares. GuruFocus notes 24 insider buys against 9 sells at Bradesco over the past year, a trailing P/E of 8.09 against an industry median of 11.58, and its own GF Value model calling the stock modestly overvalued. The Yahoo page shows BBD closing at $3.52, volume 30.4 million against a 29.4 million average, P/E 8.38, ex-dividend October 5 and next earnings estimated November 4. Note the GuruFocus piece quotes a $17.65 share price and a $35.22 billion market cap, which does not reconcile with the $3.52 close and $37.27 billion cap on the quote page, so treat its valuation arithmetic with care.
SoundHound in the Kia Sorento
SOUN is up 3.1% after announcing its voice and generative AI is now in the Kia Sorento in India, the first global deployment of the Kia AI Assistant with Real-Time Generative AI. A "Hey Kia" wake command handles climate, cabin lighting, windows and driving modes by conversation, and can pull answers from the vehicle's digital owner's manual on things like hybrid powertrain functions and seating. CEO Keyvan Mohajer supplied the quote. SoundHound says it holds more than 750 patents across automotive, financial services, healthcare, retail and telecoms. The same release ran twice on the list, from Investing.com UK and its news feed.
AMC down on a consumer promotion
AMC fell 2.6% on a day when its only news was a marketing launch, so the move isn't explained by the item. The company introduced an online booking platform for birthday parties offering up to 25% off private theatre rentals at roughly 300 US locations, bookable one to six weeks ahead, with food and beverage party packs and AMC-branded digital invitations through a partnership with Evite. Evite data cited in the release says AMC-hosted party attendance rose nearly 25% year on year, that close to 70% of movie theatre events on the platform are kid and teen birthdays, and that they are typically planned 25 days out for weekend slots. AMC runs about 850 theatres and 9,600 screens.
Iovance, new CMO plus a Wells Fargo target raise
IOVA is up 2.6% with two things behind it. Iovance named Noah Berkowitz, M.D., Ph.D., Chief Medical Officer effective Tuesday. He came from Arvinas, where as CMO he led the clinical strategy behind the first FDA approval of a targeted protein degradation therapy, and before that ran hematology at Bristol Myers Squibb, where his teams won approvals for the CAR T therapies Abecma and Breyanzi and oversaw programs contributing to Reblozyl sales above $2 billion a year. He received inducement options and RSUs covering up to 450,000 shares, options struck at $14.82, the grant-date close, vesting a third after one year then eight quarterly installments, with some RSUs tied to regulatory milestones. Separately, Wells Fargo's Yanan Zhu kept an Overweight rating and raised the target from $14 to $18. The GuruFocus write-up around that note puts Iovance's market cap near $6.63 billion, a GF Score of 37/100 with profitability ranked 1/10, and points out the company is unprofitable and cash-flow negative, so no GF Value is available and the historical median price-to-sales near 11.1 times is the reference point instead.
Generac, three conflicting reads on the same name
GNRC is down 2.5% and carries the busiest and most contradictory set of notes on the list. Citigroup kept a Neutral rating while cutting its target from $300 to $232, a 22.7% reduction, with the write-up describing a reassessment of growth prospects and risks in the current environment. Stifel's Stephen Gengaro, on the other hand, maintained Buy and nudged his target from $285 to $290. Both GuruFocus pieces lean the same way on valuation: a GF Value of $170.72 against prices of $208.44 and $212.22 in the two articles, making the stock 22% to 24% above that estimate, with a trailing P/E near 48 times versus a five-year median of 35.25. The GF Score is 87/100, strongest on profitability and growth at 8/10 each and weakest on valuation at 5/10. Insider selling totals $3,960,224 over three months, and of 15 gurus holding, 7 added and 9 trimmed. Against that, Matrix Asset Advisors' David Katz featured Generac in the firm's Q2 2026 Large Cap Value letter at a 6% allocation, citing backup power demand and product innovation while flagging supply chain constraints as a risk to production.
Take-Two consolidates its Xbox agreement
TTWO is up 2.3%. Take-Two disclosed a new long-term Xbox Publisher License Agreement with Microsoft, effective September 17, 2026, which supersedes and replaces all of its existing Xbox publisher agreements under one contract. It covers the right to develop, publish, manufacture, market, distribute and sell Xbox-compatible products across all Xbox devices. Microsoft pays the applicable wholesale price or agreed revenue share on digitally delivered products, and charges Take-Two fees and royalties on each physical unit manufactured. Microsoft retains approval rights over game concepts, final versions, packaging and marketing using its marks. Either side can terminate on material breach or insolvency, with sell-off rights for existing inventory afterward. The agreement will be filed as an exhibit to the 10-Q for the period ending September 30, 2026. GuruFocus puts GF Value near $229.58 and the GF Score at 80/100. The matching 8-K appears headline-only, as does a note on Wednesday option activity in PANW, TTWO and GLW.
Aflac, Japan Post trimming at the margin
AFL is down 1.7%, and the two GuruFocus items on it describe very small sales from a very large holder. Japan Post Holdings sold 12,200 shares at $114.55 on September 22 and 13,500 shares at $115.20 on September 23, leaving it with 50,493,590 shares, about 10.07% of Aflac and roughly 97% of its own reported equity portfolio, which consists of this single position. Both pieces read the sales as routine rebalancing given portfolio impact of about -0.02 to -0.03. On the stock itself: price $111.78, market cap $56.04 billion, P/E 11.98, ROE 16.69%, ROA 4.09%, interest coverage 24.91, Piotroski F-Score of 8, GF Score 77/100 with a weak growth rank of 2/10, and a GF Value of $129.16 putting shares about 13% below that estimate. The 14-day RSI reads 30.84. Across tracked gurus, 10 hold Aflac with 3 adding and 8 trimming. Two headline-only items sit alongside: a Form 4 dated September 30, and a GuruFocus piece whose headline asks whether AFL is undervalued on a DCF worth of $139.
Broadcom and the Anthropic lending disclosure
AVGO is down 1.1% despite the most consequential headline in the cluster: per an IPO prospectus, Broadcom will lend Anthropic up to $42 billion for infrastructure lease agreements, letting Anthropic lease Broadcom's chips. That ran across Reuters via Investing.com, GuruFocus and a market wire post, all headline-only, so the terms beyond the figure aren't available here. Other AVGO headlines are lower-grade: Netlist seeking an AI-memory import ban, Cathie Wood selling $110 million of AMD and buying Nvidia and Broadcom, net ETF buying of $143.0 million on Tuesday, and a TradingView chart note. A separate ETF flow headline shows technology as the most-bought sector on September 29.
Apple, a wall of headlines and a 1.1% gain
AAPL is up 1.1% and dominates the list by item count, though all of it is headline-only. On the sell side, Morgan Stanley cut its target to $355 from $360 while keeping Overweight, framing Apple as entering a major product cycle under new CEO John Ternus; Needham reiterated Hold citing competition risk from Meta; Bank of America flagged a risk to the stock in one headline and defended its buy rating against Muse disruption fears in another. On product: a smart-home push and new hub tied to an October 13 event, Apple Pay launching in India, iPhone 18 Pro sales up 12% in their China launch week per Counterpoint, and projections of 6 million foldable iPhone Duo units this year at $1,999. On the organization, several headlines point to Ternus targeting middle management with layoffs, with one tying the move to a memory chip crisis. The rest is ETF flow noise, roughly twenty separate items on funds buying or selling Apple alongside Nvidia.
SpaceX and the AI compute story
SPCX is up 1.1%. Needham reiterated Buy with a $250 target, pointing to announced AI compute deals reaching a combined $54 billion annualized revenue run rate and supporting a $100 billion ARR target. Macquarie is shown maintaining Outperform. ETFs bought $110.1 million of SPCX on Tuesday. Musk posts cover Starship Flight 14 and using Starship to place larger telescopes in orbit, and there are headlines on new Grok chatbot subscription pricing. All headline-only.
Oracle's data centre questions
ORCL is down 0.4% on a mixed headline set. Tencent is reported by the FT to have leased 100,000 chips from Oracle for about $7 billion to expand overseas AI capacity. Against that, Aterio flagged delay risk at Oracle's Wisconsin AI campus, and Oracle subsequently confirmed that flooding at Project Jupiter caused no major damage, with one headline noting a 5% dip. Other headlines reference a power bottleneck in the data centre buildout, congressional review of AI data centres covering Amazon, Google, Meta and Oracle, and Morgan Stanley seeing 50% upside without a Buy. Headline-only throughout.
Smaller movers and single-line items
The rest is thinner. COST is down 1.5% with nothing but a Frates insider sale of 801 shares, a Form 4, an ETF flow line and a geopolitical wire post on Iran and defence stocks that has no evident link to Costco. NFLX is down 1.0% against headlines that its co-CEO voiced growth concerns, saying the company is not growing as fast as he wants. VICR is down 0.6% even though the headlines are positive: it raised Q3 sequential growth guidance to over 30% on a new licensing deal, prompting a Needham target of $350, with several items describing a 10% surge, so the quote and the news are pointing opposite ways today. NBIS is down 0.6% with William Blair initiating at Outperform and a 12-year, 50 MW data centre deal with AIB. NVTS gained after early FTC clearance for the Claros acquisition, ASTS shipped three more BlueBird satellites, NTAP is up 0.4% on its Novus storage launch and a BofA target raise to $220, EXEL headlines note an all-time high at $59.73, RKLB has a 20-mission Synspective contract, and SNDK, TEVA, ALAB, MPC, TSM, PGY, PL, CMP, BBAI and SRFM carry one-line items with moves under a percent.
Brazilian banks lead the board
Itaú Unibanco was the biggest mover on the list, up 5.4% to $8.53, with Bradesco up 4.9% to $3.525 right alongside it. Neither of those items is news, they're Yahoo Finance quote pages, so there's no stated reason for the move in the material. What's there is context: ITUB traded 51.2 million shares against a 20.7 million average, put in a 13.7% month and 18.5% year to date, trades on a 10.5 trailing P/E with a $8.88 one-year target average, and JP Morgan maintained Overweight on 7 July while lifting its target from $9 to $10. Bradesco moved on 28.9 million shares, roughly its normal 29.8 million average, is up 8.5% on the month but only 4% year to date, sits at an 8.4 P/E with a 4.86% forward yield and a $4.30 average target. Santander Brasil was down 2.1% on the same screens, so this wasn't a clean sweep of Brazilian financials, but the two big private banks moving together this hard on no company-specific news is worth a look at the Brazil macro tape.
SoundHound lands Kia India
SoundHound was up 3.4% after announcing its voice and generative AI is now running in the Kia Sorento in India. This is the first global deployment of the Kia AI Assistant with Real-Time Generative AI, using a "Hey Kia" wake word to control climate, cabin lighting, windows and driving modes by speech, plus access to the digital owner's manual, point-of-interest navigation and news. CEO Keyvan Mohajer supplied the quote. No financial terms were disclosed. The company notes it holds over 750 patents. Two outlets carried the same press release, so treat it as one item, not two.
TMC adds an Exxon veteran to the board
The Metals Company was up 2.8% after naming Liam Mallon, a 35-year ExxonMobil executive, to its board and as chair of a new Sustainability and Innovation Committee. The timing is tied to the US government moving toward issuing deep-sea mining permits. TMC applied for US authorisation in 2025 to recover polymetallic nodules from the Clarion-Clipperton Zone containing nickel, copper, cobalt and manganese. It has no revenue, market cap of $1.67 billion, GF Score 37 out of 100 with profitability at 1 out of 10, and is down over 38% year to date, trading near its 52-week low of $3.40 against an $11.35 high. Insiders sold $2.4 million over twelve months with no purchases, while three gurus added.
AMC down, and mind which AMC
AMC was down 2.8%, and the two articles here are about different companies, so read them carefully. One covers AMC Networks (AMCX), which fell 4.1% on 29 September to $11.54, up 21.2% year to date, with GuruFocus calling it 24.9% overvalued against a $9.24 GF Value and flagging $0.2 million of insider selling with no buying. The other covers AMC Entertainment (AMC), which was the top communication services performer in September with a 27.03% monthly gain, market cap $2.73 billion, GF Score 52 with momentum at 9 but financial strength at 2, a distressed Altman Z-score of -0.87 and interest coverage of 0.49. Insiders there were net buyers of $345,000 over twelve months with no selling, and two of three gurus added. Today's move gives some of that September run back.
Generac, three angles and a gap
Generac was down 2.5%, which sits against a stack of constructive items. It rose 3.4% on 29 September to $212.22, within a 52-week range of $134.80 to $296.44. Stifel's Stephen Gengaro maintained Buy and nudged the target from $285 to $290 (the GuruFocus piece dates that action to October 2023, so the date is suspect). Matrix Asset Advisors disclosed a 6.0% allocation in its Q2 2026 large-cap value letter, with David Katz citing demand for backup power. TradeStation's TradingView note points to the 17 September gap higher on Amazon entering a long-term supply agreement that included warrants in Generac, with the stock holding in or above that gap, pushing above its 50-day average, the 8-day EMA crossing the 21-day and MACD rising. The counterweight in the same material: GF Score 87 but valuation 5 out of 10, a 48.9x trailing P/E versus a 35.4x five-year median, GuruFocus calling it roughly 24% overvalued, and $17.6 million of insider selling over twelve months with no buying.
Iovance after the guidance raise
Iovance was up 2.4%, an add-on to a much larger move. On 29 September the stock jumped over 30% after raising 2026 revenue guidance to $410-420 million against consensus near $403 million, close to 60% year-over-year growth. Goldman's Andrea Newkirk resumed coverage at Buy with a $15 target, citing Q2 Amtagvi sales of $91 million across 150 patients and arguing availability constraints are easing. Wells Fargo's Yanan Zhu kept Overweight and lifted the target from $14 to $18; HC Wainwright's Joseph Pantginis kept Buy and went from $9 to $20. Against that, the company is still unprofitable with a -91.17% operating margin, trades at 18.7x sales versus an 11.1x historical median, and carries a GF Score of 38 with profitability 1 out of 10, offset by financial strength of 7 and an Altman Z of 11.97.
Take-Two options volume
Take-Two was up 2.3% and showed up in a Nasdaq options-activity piece: 10,536 contracts traded, about 1.1 million underlying shares, or 41.8% of its 2.5 million average daily volume. The concentration was in the $240 strike call expiring 20 November, 858 contracts. Palo Alto and Corning appeared in the same note.
Aflac and Costco valuation notes
Aflac was down 1.6%, with a Form 4 filing headline and a DCF piece that lands on contradictory answers: earnings-based intrinsic value of $139.44 against a $113.66 price (18.5% margin of safety), but an FCF-based value of $54.13, which would make it heavily overvalued. GF Value sits at $129.16, GF Score 78, and the predictability rank is 0 out of 5, which the article itself flags as making the DCF unreliable. Insiders sold $222.5 million over the past year and eight of ten gurus trimmed. Costco was down 1.5%; its item has GF Value at $1,047.55 versus a $924.59 price, so 11.7% undervalued on that measure, a GF Score of 95 with growth and valuation both 10 out of 10 but momentum at 5, and $19.0 million of insider selling with no buying.
Apple, a large cluster with no single driver
Apple was up 1.2% and dominates the list by headline count, but all of it is headline-only. The recurring threads: John Ternus has taken over as CEO after Tim Cook and headlines point to a management shake-up targeting middle management and faster product cycles, with one headline mentioning layoffs amid a memory chip crisis. A smart-home hub launch is flagged for October 13. Counterpoint data has iPhone 18 Pro sales up 12% in China launch week. A foldable "iPhone Duo" at $1,999 is projected at 6 million units this year. Apple Pay launched in India. Bank of America is cited both defending its buy rating and flagging an AI threat from Meta's Muse. A long run of ETF flow headlines (SPY, QQQ, IVV, XLK and others buying or selling Apple) is routine index mechanics, not company news. Nothing here is read in full, so treat all of it as a pointer rather than substance.
The quieter names
The rest is mostly minor moves and headline-only flow. Navitas was down 1.1% on FTC clearance for its Claros acquisition and options activity; Broadcom also down 1.1% with headlines on Netlist seeking an AI-memory import ban and Cathie Wood buying. SpaceX was up 1.0% with a dense headline run on Starship Flight 14, a Needham Buy reiteration at $250 citing $54 billion of annualised AI compute deals, and Macquarie at Outperform. Netflix was down 1.0% despite a Deutsche Bank upgrade to Buy with the target cut from $100 to $95, plus exclusive WWE streaming rights in Japan from October 1. NetApp was up 0.4% on a heavy product-news day (Novus storage architecture, AI data engine updates, Supermicro partnership) and a BofA target raise to $220. Nebius was down 0.5% on a 12-year, 50 MW data centre deal with AIB. Oracle was down 0.3%, with headlines on reported delays at its Wisconsin AI campus and congressional scrutiny of AI data centres. Pagaya and Revolution Medicines both had routine insider sale Form 4s. Exelixis hit an all-time high of $59.73 while finishing down 0.4%. One incidental detail from the market wrap: Credo's COO Yat Tung Lam sold 100,000 shares at $206.29, about $20.63 million.
Macro backdrop in the source pages
Worth noting because it sits under several of these names: core PCE for August came in at +0.2% month-on-month, cooler than expected, and the Investing.com pages report October Fed hike bets fading on that plus dovish comments. The 10-year was at 5.29-5.30, up on the day, S&P 500 down 0.25%, Dow down 0.86%, Nasdaq up 0.24%.
Iovance jumps on raised 2026 guidance
IOVA is up 31.5%, the standout on the list, after the company filed an 8-K raising full-year 2026 revenue guidance to $410-420 million from a prior $350-370 million. That is roughly 15% higher at the midpoint, above the $402.8 million analyst consensus, and implies close to 60% annual growth. Management tied it to sustained and accelerating US demand for Amtagvi (lifileucel) and Proleukin. Interim President and CEO Frederick Vogt pointed to a record second quarter, $99.3 million of product revenue at a 56% gross margin, and said manufacturing schedules and patient demand give visibility into Q3 and Q4. The authorized treatment center network is approaching 100 with a year-end target of at least 110, and Q3 results are due in early November. The stock hit a 52-week high of $11.17 at the open after trading at $12.15 pre-market. Two supporting analyst items sit alongside this: Goldman Sachs' Andrea Newkirk resumed coverage days earlier with a Buy and a $15 target, citing $91 million of Amtagvi sales across 150 patients in Q2 and easing availability constraints, and HC Wainwright's Joseph Pantginis maintained Buy with the target raised from $9 to $20, though that GuruFocus write-up carries a confused internal date and is thin on new reasoning. Worth noting the GuruFocus pieces flag the valuation stretch, price-to-sales at 13.9 to 18.7 against an 11.1 historical median, with the company still unprofitable and cash-flow negative.
Sharp decliners with little explanation
BeyondSpring is down 31.0% on a headline-only 8-K covering entry into a material definitive agreement plus other events. The filing's contents aren't in the material here, so the driver of the move isn't established. VerifyMe is down 17.8% with only a Form 4 insider filing in the list, and that Investing.com item contains no detail on who traded or how much, so again no stated cause.
AMC down 6.4% after a strong month
AMC Entertainment fell 6.4%. The two full-read pieces are both backward-looking GuruFocus screens rather than news. One notes AMC closed September as the best-performing communication services stock, up 27.03% over the month, with a P/S of 0.34 against a 0.25 historical median, a GF Score of 52, a distressed Altman Z-score of -0.87, interest coverage of 0.49, negative TTM EPS of -1.06, and GF Value of $1.84 against roughly $3.06 trading. Insiders bought a net $345,000 over twelve months with no selling, and three gurus hold with two adding. Neither article gives a reason for today's decline. The second piece actually covers AMC Networks (AMCX), a different company, down 4.1% to $11.54, which GuruFocus calls 24.9% overvalued against a $9.24 GF Value.
Axsome down 4% with heavy put buying
AXSM fell 4.0% and the options tape is the story. Investing.com reports 92.7% of the day's volume was put-side, 1,922 puts against 151 calls, dominated by a fresh 1,200 by 600 ratio put spread expiring October 16: 600 long $185 puts and 1,200 long $170 puts. The $170 strike had prior open interest of just one contract, so this is new positioning rather than a roll. Three-month implied vol rose 2.37 points to 45.95% and 90/110 skew rose 0.30 points to 1.26. Context cited: the stock is down 23.82% over three months from a peak near $260, the ENGAGE Phase III readout for solriamfetol in binge eating disorder is due in Q4 2026, the CEO sold roughly $23.9 million of stock in June and July, and Q1 2026 missed on EPS ($1.26 loss versus $0.83 expected). Separately, Deutsche Bank's David Hoang kept a Buy but cut his target from $280 to $267, a 4.6% trim, with the note describing a cautious read on recent performance and market sentiment rather than anything company-specific. GuruFocus records $24.56 million of insider selling over three months.
Oracle up 3.9% on OpenAI revenue report
ORCL rose 3.9%, the largest gainer after IOVA among the names with real content. Investor's Business Daily attributes the move to an Axios report that OpenAI's annualized revenue run rate has reached close to $70 billion on enterprise sales, up more than 70% since the start of the year, which lifted Oracle and other OpenAI-linked names despite news that OpenAI scrapped a release plan for its next-generation model. The analyst debate is about returns rather than demand. Morgan Stanley's Sanjit Singh kept Equal Weight with a $210 target even while seeing about 50% upside, wanting evidence that the $90-95 billion annual capex reaffirmation converts into gross margin stability; the October 28 financial analyst day is flagged as the next checkpoint. Oracle reported $11.6 billion in quarterly cloud revenue, up 62%, with cloud infrastructure more than doubling to $7.4 billion and OCI up 121% year over year, against negative $5 billion free cash flow. Oppenheimer put Oracle among software vendors with AI businesses above $1 billion but noted buyers now want measurable returns. On the product side, Oracle Financial Services launched Nexus Case Flow and Nexus Reach, two AI tools for financial crime investigation, at the ACAMS conference in Las Vegas. Less helpfully, Oracle is one of four firms, with Amazon, Google and Meta, that House Judiciary member Jamie Raskin has asked to disclose confidentiality agreements with government officials over AI data center projects, an inquiry aimed at NDAs that keep communities in the dark about electricity, water and local finance implications. Three headline-only items round it out: an $18 billion Oracle AI project reportedly hitting a hurdle, a Form 4 insider filing, and a chart piece.
Mid-single-digit movers, headline only
Rocket Lab is down 3.4% and TMC down 3.1%, the latter alongside an 8-K and coverage of former ExxonMobil executive Liam Mallon joining the board ahead of a deep-sea mining push. Generac is up 3.4% with two conflicting-looking headlines, a GuruFocus piece on the 3.4% gain and a GF Score of 87, and a Jefferies price target cut on execution concerns. Mercury Systems is up 3.1%. All headline-only, so no detail behind them.
Apple down 2.7% on management shake-up headlines
AAPL fell 2.7% and carries by far the most headlines, though none were read in full. The recurring threads: new CEO John Ternus reportedly targeting middle management with layoffs and faster product development; a major smart-home push said to launch October 13; Apple Pay launching in India; iPhone 18 Pro sales up 12% in China launch week per Counterpoint; and Bank of America flagging an AI-related risk to the stock. Morgan Stanley reiterated with the target held at $360. A large share of the remaining Apple lines are routine daily ETF flow reports from GuruFocus rather than news.
SpaceX up 2.6% on AI compute thesis
SPCX rose 2.6%, with the headlines clustered around AI compute leasing rather than launch. Needham reiterated Buy at a $250 target, citing announced compute deals reaching a combined $54 billion annualized revenue run rate. TD Cowen initiated at Buy with a $200 target, expecting AI compute leasing to become the largest business by Q1 2027. BofA reiterated Buy after the Starship orbital test. Also in the list: a reported Starship engine failure that could affect NASA moon mission objectives, NASA giving Boeing Starliner a $359 million lifeline, and Beeline/VEON launching Starlink satellite-to-mobile in Kazakhstan.
Netflix upgraded, up 1.5%
NFLX gained 1.5% after Deutsche Bank upgraded to Buy from Hold while cutting the target to $95 from $100, the stated reasoning being global scale, an international production advantage and valuation at roughly 18x estimated earnings. Separately, Netflix secured exclusive WWE streaming rights in Japan from October 1. Headline-only.
The quieter rest
NetApp is up 2.3% on a dense run of product headlines from its INSIGHT conference: the Novus storage architecture for AI workloads, AI data engine updates, an expanded Commvault tie, a Supermicro partnership, a European data sovereignty service, and a BofA target raise to $220. Nebius up 2.4% on a 50 MW data center deal with AIB. Astera Labs up 1.9%, Broadcom up 1.6%, TSMC up 0.9% on 2nm expansion chatter, SanDisk up 1.0%, Marathon Petroleum up 0.7%, Constellation Software up 0.6%. Pagaya is up 2.2% against three separate insider sales, president Sanjiv Das at $243,672, CFO Jonathan Dobres at $10,053, and CAO Cory Vieira at $36,976. Butterfly Network was initiated at Outperform by Evercore ISI. Amphenol, Costco, Aflac, Navitas and the remainder are essentially flat with only screening or ETF-flow items behind them.
Iovance up 32% on a big guidance raise
IOVA is the day's outlier, up 32.1%, and the reason is concrete. In a Form 8-K filed Tuesday morning, Iovance lifted full-year 2026 total revenue guidance to $410-$420 million from $350-$370 million, roughly 15% higher at the midpoint, above the analyst consensus of about $402.8 million and implying close to 60% annual growth. Management attributed it to sustained and accelerating demand for Amtagvi (lifileucel) and Proleukin across US treatment centres. Interim President and CEO Frederick Vogt pointed to the record second quarter, $99.3 million of product revenue at a 56% gross margin, as giving visibility into the back half, and the update closes out the formal review flagged when Q2 was reported in August. The authorised treatment centre network is approaching 100 with a year-end target of at least 110. The stock hit a 52-week high of $11.17 at the open and closed at $14.45, up 31.48% on the day, on volume of roughly 75.8 million shares against a 16.6 million average. Q3 results are due 5 November.
The analyst side of the Iovance move
Two separate notes sit behind and alongside the guidance. Goldman Sachs resumed coverage days earlier, analyst Andrea Newkirk with a Buy and a $15 target, citing Amtagvi's Q2 of $91 million in sales across 150 patients, easing availability constraints, and a proprietary physician survey showing strong demand for the drug as second-line melanoma treatment. Separately, HC Wainwright's Joseph Pantginis maintained Buy and raised his target from $9 to $20, though note that GuruFocus item is internally inconsistent on dates, it is tagged 29 September 2026 but describes the action as taken on 24 October 2023. The GuruFocus coverage also flags the other side: Iovance is still unprofitable, with TTM profit margin around -89%, negative free cash flow, and a price-to-sales ratio well above its historical median of about 11. One of the five IOVA items also headlines the move as +19.2% on volume 0.3x average, which contradicts the closing data on the same page showing +31.48% on 4.6x average volume, so treat that line as unreliable.
BeyondSpring and VerifyMe both down hard
BYSI is down 31.0% and the only item is an 8-K covering entry into a material definitive agreement plus other events. Headline only, so the contents of that agreement aren't described here, and it's the obvious thing to pull the filing on. VRME is down 14.3% against a Form 4 insider filing and an 8-K exhibit filing; the Form 4 article carried no body text at all, so there's no detail on who traded or how much.
AMC down 7.1% after a strong month
AMC fell 7.1%. The GuruFocus piece is backward-looking rather than an explanation of today: it notes AMC was the best performer in communication services over the past month, up 27.03%, with net insider buying of $345,000 over twelve months and no insider selling, and three gurus holding with two adding. It also sets out the weak side, an Altman Z-score of -0.87, interest coverage of 0.49, TTM EPS of -1.06, and a GF Value of $1.84 against a price around $3.06. A TradingView post from a retail author describes a daily double-bottom breakout with support at $2.70-$2.80. Nothing in either item accounts for today's decline.
Oracle up 4% with genuinely mixed news
ORCL rose 4.0% to $137.91 on 42.6 million shares. The likely driver is the OpenAI read-across: Investor's Business Daily, citing Axios, reports OpenAI's annualised revenue run rate has grown more than 70% since the start of the year to close to $70 billion on enterprise sales strength, which lifted Oracle and other OpenAI-linked names even as OpenAI scrapped a release plan for its next model. Against that, a Reuters-sourced GuruFocus piece describes Oracle invoking force majeure over Project Jupiter, the 1,400-acre STACK Infrastructure data centre in New Mexico built for OpenAI, which may slip about a year on power procurement difficulties. The project has raised roughly $18 billion in loans with about $3 billion of Blue Owl equity, and Blue Owl earns 9% during development rising to around 11% levered once complete. Blue Owl says the notice doesn't change its commitments. Elsewhere, Oppenheimer put Oracle among software vendors with AI businesses over $1 billion while noting buyers now want measurable returns; Oracle reported $11.6 billion of quarterly cloud revenue, up 62%, with cloud infrastructure more than doubling to $7.4 billion, but free cash flow of negative $5 billion. Oracle Financial Services also launched two AI products for financial crime investigation, Nexus Case Flow and Nexus Reach, at the ACAMS conference in Las Vegas. Two GuruFocus valuation pieces put GF Value at $193.13 against Monday's $132.60 close, a 31.3% discount, but tag it a possible value trap, and note insiders sold $119.1 million over twelve months with no buying. Three further Oracle headlines, all headline-only, point the other way on sentiment: Meta's enterprise AI push knocking Microsoft and Oracle, and oncology AI entering the EHR.
SpaceX, the biggest headline cluster
SPCX rose 2.7% and carries more items than anything else on the list, all headline-only. The recurring threads are Starship Flight 14, described as the first orbital flight with 26 Starlink V3 satellites deployed despite an engine failure, and a wave of analyst initiations and reiterations around it: TD Cowen starting at Buy with a $200 target and expecting AI compute leasing to become SpaceX's largest business by Q1 2027, CLSA initiating with a $250 target, Deutsche Bank maintaining $235, and BofA and Clear Street reiterating Buy. Separate headlines flag the engine failure's possible impact on NASA's moon objectives, NASA giving Boeing Starliner a $359 million lifeline, and VEON/Beeline launching Starlink satellite-to-mobile in Kazakhstan. Rocket Lab, down 3.6%, appears alongside a headline on Goldman flagging SpaceX in a growth screen and a Cathie Wood $64 million purchase across two stocks.
Apple weak, Netflix upgraded
AAPL fell 2.7% with a large but thin set of headlines: Morgan Stanley reiterating a $360 target, several pieces framing Meta's AI Muse and local desktop AI as a competitive threat, BofA flagging a new AI risk, and reports that new CEO John Ternus is reworking product development and launch strategy. Much of the rest is routine ETF flow reporting. NFLX gained 1.5% on a Deutsche Bank upgrade to Buy from Hold, with the target cut to $95 from $100, the stated reasoning being global scale, an international production advantage and valuation at roughly 18x estimated earnings. Netflix also picked up exclusive WWE streaming rights in Japan from 1 October.
The smaller movers
AXSM fell 3.9%, with headlines on heavy put skew in options ahead of a binary catalyst and a Deutsche Bank target cut to $267. GNRC rose 3.4% despite a Jefferies target cut on execution concerns. TMC fell 3.1% as it added ExxonMobil veteran Liam Mallon to its board ahead of a seabed mining push, confirmed by an 8-K. NTAP gained 2.4% amid a heavy product news day, a Novus storage architecture for AI workloads, AI data engine updates, a Supermicro partnership and a European data sovereignty service, alongside a note that CEO George Kurian sold 37,000 shares. SIBN rose 2.0% on FDA clearance of its iFuse Granite Onyx system. Smaller items: TEVA up 2.4% on FDA approval of the Degevma biosimilar, JOBY down 2.4% with a $45 million contract ceiling increase for an autonomous cargo project, SRFM down 1.7% naming Jason Secore CFO, RVMD up 1.4% with a Brookline Capital Buy initiation and an officer selling $743k, and BFLY down 0.6% on an Evercore ISI Outperform initiation.
Quiet names
The rest of the list is largely routine. AVGO, TSM, SNDK, VRT, CRDO, MPC, COST, APH, WULF, NVTS, AFL, AU, KGS, ALAB and PGY all moved 2% or less, and their items are ETF flow tallies, GF Value screens and single-line analyst notes with nothing new behind them.
TradingView
Trading 212
